ESMO 2026
The ESMO Congress is a highly influential global oncology meeting for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world.
ESMO 2026 will be a platform for breakthroughs in oncology research, clinical practice and patient care.
Participants can expect impactful new data, interactive education, excellent networking opportunities and an innovative exhibition area.
By attending the ESMO Congress 2026, oncologists will not only gain insights into the latest developments but also play an active role in shaping the future of oncology on a global scale.
ESMO 2026: Sacituzumab tirumotecan effective at decreasing recurrence of and death from endometrial cancer
ESMO 2026: New targeted therapy improved survival for patients with KRAS-mutated lung cancer
ESMO 2026: Nearly one third of patients with advanced melanoma saw tumours disappear completely after receiving TIL therapy plus pembrolizumab immunotherapy
ESMO 2026: New treatment combination shows promising results in recurrent head and neck cancer
ESMO 2026: Immunotherapy combination extends survival in advanced endometrial cancer
ESMO 2026: Cancer care coordination study presented
ESMO 2026: Patients with a form of advanced lung cancer lived 56% longer without their disease progressing after receiving radiotherapy in addition to standard treatment
ESMO 2026: Immunotherapy combo extends survival for patients with aggressive small cell lung cancer
ESMO 2026: Adding abiraterone to ADT and docetaxel improves survival in metastatic prostate cancer
ESMO 2026: Novel cancer immunotherapy drug generates promising clinical trial results
ESMO 2026: Perioperative apalutamide in high-risk localised or locally advanced prostate cancer substudy supports reduced risk of metastasis and death
ESMO 2026: New analysis reinforces survival benefits of targeted therapy for advanced pancreatic cancer
ESMO 2026: Diagnostic test could help doctors refine prostate cancer treatment
ESMO 2026: Bladder and kidney cancer roundup
ESMO 2026: Prostate cancer roundup
Outpatient administration of xaluritamig for mCRPC: Feasibility and safety
Personalised neoantigen vaccine plus radiotherapy improves progression free survival in advanced solid tumours
Tarlatamab improves long term survival in previously treated small cell lung cancer
Mocertatug rezetecan shows promising activity in platinum-resistant ovarian cancer
ABBV-706 shows promising antitumour activity in R/R SCLC
Arcotatug tavatecan improves progression-free survival in CLDN18.2-positive advanced gastric cancer
Zanidatamab plus chemotherapy improves overall survival in HER2-positive advanced gastroesophageal cancer
STRIDE-based immunotherapy plus TACE shows promising outcomes in embolisation-eligible HCC
Darolutamide plus ADT and radiotherapy improves metastasis free survival in very high risk prostate cancer
ESMO 2026: Surgery in high-risk localised prostate cancer
Omega-3 EPA improves overall survival after colorectal cancer liver metastasis resection
Updated survival and ctDNA findings support adjuvant cemiplimab in high-risk CSCC
Long-term survival benefits of abiraterone in de novo metastatic prostate cancer
Divarasib improves survival in previously treated KRAS G12C mutated advanced NSCLC
Tarlatamab plus durvalumab improves survival in extensive-stage small cell lung cancer
Real-world outcomes with tarlatamab in previously treated ES-SCLC
Risvutatug rezetecan improves PFS in relapsed or refractory osteosarcoma
Reduced dosing frequency of immune checkpoint inhibitors raises survival concerns in advanced cancer
Pembrolizumab improves PFS and QoL in dMMR advanced endometrial cancer
Sacituzumab tirumotecan reduces progression and death in recurrent endometrial cancer
ESMO 2026: Highlights and analysis
Dostarlimab achieves durable complete clinical responses in dMMR/MSI-H locally advanced rectal cancer
Lifileucel plus pembrolizumab shows durable responses in first-line advanced melanoma
T-cell engagers in mAPMR/mCRPC
Short course durvalumab remodels the tumour immune microenvironment in early stage triple negative breast cancer
Intismeran plus pembrolizumab improves recurrence free survival in resected high risk melanoma
Adding nivolumab to perioperative chemo shows no significant benefit in muscle invasive bladder cancer
ESMO 2026: Advances in NMIBC and MIBC
Perioperative apalutamide plus ADT improves event free survival in high risk localised prostate cancer
AI-based digital MammaPrint assay predicts recurrence risk and survival in early-stage breast cancer
UV1 vaccine combination shows no significant PFS improvement in BRCA wild type recurrent ovarian cancer
HBI-8000 plus nivolumab significantly improves progression-free survival in advanced melanoma
Camupepimut shows early disease free survival signal in resected KRAS mutated pancreatic cancer
TALENT: Neoadjuvant T-DXd with or without anastrozole, or in sequence with chemo for HER2-low, HR+ early-stage breast cancer
AI tool identifies patients most likely to benefit from extended endocrine therapy in hormone receptor-positive breast cancer
Extended letrozole improves disease-free survival in hormone receptor-positive breast cancer: 15-year results
Perioperative pembrolizumab fails to significantly improve event-free survival in muscle-invasive bladder cancer
Sacituzumab govitecan combination shows promising activity in first line metastatic urothelial cancer